Recent investigations on the mechanism [19] disclosed that, trifolium flavonoids could significantly reduce the phosphorylation levels of STAT3 and ERK, which suggested that both STAT3 and ERK signaling pathways may be potential biotargets of trifolium flavonoids to enhance the gefitinib’s effects on NSCLC cells. The gene discussed is MAPK1; the disease is non-small cell lung carcinoma.